Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tevogen Inc.TVGN · Entity 7276 | See Remarks | March 10, 2026 | March 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tevogen Inc.
Report date March 10, 2026 · Filed March 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 76,940 |
Ending reported balance
After 2026-03-13 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-03-10 · Sale · Disposed 19 · Balance 77,893 F1: The sales reported on this Form 4 were made solely to satisfy the payment of tax obligations relating to the vesting and subsequent settlement of restricted stock units. Such sales were not made at the discretion of the reporting person. Row 2 · 2026-03-11 · Sale · Disposed 452 · Balance 77,441 F1: The sales reported on this Form 4 were made solely to satisfy the payment of tax obligations relating to the vesting and subsequent settlement of restricted stock units. Such sales were not made at the discretion of the reporting person. F2: The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4. F3: These shares were sold in multiple transactions at prices ranging from $7.25 to $7.33, inclusive. Row 3 · 2026-03-13 · Sale · Disposed 501 · Balance 76,940 F1: The sales reported on this Form 4 were made solely to satisfy the payment of tax obligations relating to the vesting and subsequent settlement of restricted stock units. Such sales were not made at the discretion of the reporting person. F2: The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4. F4: These shares were sold in multiple transactions at prices ranging from $6.39 to $6.74, inclusive. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 were made solely to satisfy the payment of tax obligations relating to the vesting and subsequent settlement of restricted stock units. Such sales were not made at the discretion of the reporting person.
F2: The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4.
F3: These shares were sold in multiple transactions at prices ranging from $7.25 to $7.33, inclusive.
F4: These shares were sold in multiple transactions at prices ranging from $6.39 to $6.74, inclusive.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 13, 2026 Filed Mar 17, 2026 16:29 UTC | Tevogen Inc. TVGN · Entity 7276 | SaleCommon Stock | 501 | $6.40 | $3,206.40 |
DisclosureSEC source: 0001123292-26-000465 · form4.xml · nonDerivative · entry 3 Flomenberg Neal · CIK 0002011757 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,940 F1 · kind: The sales reported on this Form 4 were made solely to satisfy the payment of tax obligations relating to the vesting and subsequent settlement of restricted stock units. Such sales were not made at the discretion of the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4. F4 · price: These shares were sold in multiple transactions at prices ranging from $6.39 to $6.74, inclusive. Read SEC document |
| March 11, 2026 Filed Mar 17, 2026 16:29 UTC | Tevogen Inc. TVGN · Entity 7276 | SaleCommon Stock | 452 | $7.26 | $3,281.52 |
DisclosureSEC source: 0001123292-26-000465 · form4.xml · nonDerivative · entry 2 Flomenberg Neal · CIK 0002011757 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,441 F1 · kind: The sales reported on this Form 4 were made solely to satisfy the payment of tax obligations relating to the vesting and subsequent settlement of restricted stock units. Such sales were not made at the discretion of the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4. F3 · price: These shares were sold in multiple transactions at prices ranging from $7.25 to $7.33, inclusive. Read SEC document |
| March 10, 2026 Filed Mar 17, 2026 16:29 UTC | Tevogen Inc. TVGN · Entity 7276 | SaleCommon Stock | 19 | $7.75 | $147.25 |
DisclosureSEC source: 0001123292-26-000465 · form4.xml · nonDerivative · entry 1 Flomenberg Neal · CIK 0002011757 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,893 F1 · kind: The sales reported on this Form 4 were made solely to satisfy the payment of tax obligations relating to the vesting and subsequent settlement of restricted stock units. Such sales were not made at the discretion of the reporting person. Read SEC document |
| June 27, 2025 Filed Jul 1, 2025 16:49 UTC | Tevogen Inc. TVGN · Entity 7276 | GrantCommon Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-012329 · form4.xml · nonDerivative · entry 1 Flomenberg Neal · CIK 0002011757 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,895,608 F1 · shares: Represents a grant of restricted stock under the Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan, which will vest ratably in three equal annual installments commencing on June 27, 2030, provided that the reporting person remains in service with the Issuer at such dates. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 21:02 UTC | Tevogen Inc. TVGN · Entity 7276 | SaleCommon Stock | 232,968 | $1.09 | $253,935.12 |
DisclosureSEC source: 0001062993-25-005533 · form4.xml · nonDerivative · entry 1 Flomenberg Neal · CIK 0002011757 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,595,608 F1 · kind: The sales reported on this Form 4 were made solely to satisfy the payment of tax obligations relating to the vesting and subsequent settlement of restricted stock units. Such sales were not made at the discretion of the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.05 to $1.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 11, 2025 Filed Mar 11, 2025 20:52 UTC | Tevogen Inc. TVGN · Entity 7276 | SaleCommon Stock | 70,252 | $1.05 | $73,764.60 |
DisclosureSEC source: 0001062993-25-005198 · form4.xml · nonDerivative · entry 3 Flomenberg Neal · CIK 0002011757 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,828,576 F1 · kind: The sales reported on this Form 4 were made solely to satisfy the payment of tax obligations relating to the vesting and subsequent settlement of restricted stock units. Such sales were not made at the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (5) to this Form 4. F5 · price: These shares were sold in multiple transactions at prices ranging from $1.02 to $1.085, inclusive. Read SEC document |
| March 10, 2025 Filed Mar 11, 2025 20:52 UTC | Tevogen Inc. TVGN · Entity 7276 | SaleCommon Stock | 70,384 | $1.09 | $76,718.56 |
DisclosureSEC source: 0001062993-25-005198 · form4.xml · nonDerivative · entry 2 Flomenberg Neal · CIK 0002011757 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,898,828 F1 · kind: The sales reported on this Form 4 were made solely to satisfy the payment of tax obligations relating to the vesting and subsequent settlement of restricted stock units. Such sales were not made at the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (5) to this Form 4. F4 · price: These shares were sold in multiple transactions at prices ranging from $1.05 to $1.14, inclusive. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 20:52 UTC | Tevogen Inc. TVGN · Entity 7276 | SaleCommon Stock | 71,273 | $1.14 | $81,251.22 |
DisclosureSEC source: 0001062993-25-005198 · form4.xml · nonDerivative · entry 1 Flomenberg Neal · CIK 0002011757 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,969,212 F1 · kind: The sales reported on this Form 4 were made solely to satisfy the payment of tax obligations relating to the vesting and subsequent settlement of restricted stock units. Such sales were not made at the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (5) to this Form 4. F3 · price: These shares were sold in multiple transactions at prices ranging from $1.065 to $1.185, inclusive. Read SEC document |
| March 06, 2025 Filed Mar 6, 2025 21:41 UTC | Tevogen Inc. TVGN · Entity 7276 | SaleCommon Stock | 88,519 | $1.10 | $97,370.90 |
DisclosureSEC source: 0001062993-25-004850 · form4.xml · nonDerivative · entry 3 Flomenberg Neal · CIK 0002011757 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,040,485 F1 · kind: The sales reported on this Form 4 were made solely to satisfy the payment of tax obligations relating to the vesting and subsequent settlement of restricted stock units. Such sales were not made at the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (5) to this Form 4. F5 · price: These shares were sold in multiple transactions at prices ranging from $1.06 to $1.19, inclusive. Read SEC document |
| March 05, 2025 Filed Mar 6, 2025 21:41 UTC | Tevogen Inc. TVGN · Entity 7276 | SaleCommon Stock | 110,659 | $1.21 | $133,897.39 |
DisclosureSEC source: 0001062993-25-004850 · form4.xml · nonDerivative · entry 2 Flomenberg Neal · CIK 0002011757 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,129,004 F1 · kind: The sales reported on this Form 4 were made solely to satisfy the payment of tax obligations relating to the vesting and subsequent settlement of restricted stock units. Such sales were not made at the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (5) to this Form 4. F4 · price: These shares were sold in multiple transactions at prices ranging from $1.16 to $1.29, inclusive. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:41 UTC | Tevogen Inc. TVGN · Entity 7276 | SaleCommon Stock | 14,639 | $1.28 | $18,737.92 |
DisclosureSEC source: 0001062993-25-004850 · form4.xml · nonDerivative · entry 1 Flomenberg Neal · CIK 0002011757 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,239,663 F1 · kind: The sales reported on this Form 4 were made solely to satisfy the payment of tax obligations relating to the vesting and subsequent settlement of restricted stock units. Such sales were not made at the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (5) to this Form 4. F3 · price: These shares were sold in multiple transactions at prices ranging from $1.27 to $1.32, inclusive. Read SEC document |
| October 17, 2024 Filed Oct 18, 2024 21:57 UTC | Tevogen Inc. TVGN · Entity 7276 | SaleCommon Stock | 1,078,600 | $1.62 | $1,747,332.00 |
DisclosureSEC source: 0001062993-24-017785 · form4.xml · nonDerivative · entry 1 Flomenberg Neal · CIK 0002011757 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,254,302 F1 · kind: The sales reported on this Form 4 were made solely to satisfy the payment of tax obligations relating to the vesting and subsequent settlement on the transaction date of restricted stock units. Such sales were not made at the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.50 to $1.74, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 17:25 UTC | Tevogen Inc. TVGN · Entity 7276 | GrantCommon Stock | 5,332,902 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-24-003490 · form4.xml · nonDerivative · entry 1 Flomenberg Neal · CIK 0002011757 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,332,902 F1 · price: On February 14, 2024 (the "Effective Date"), pursuant to that certain Agreement and Plan of Merger, dated as of June 28, 2023, by and among the Issuer, Semper Merger Sub, Inc., and Tevogen Bio Inc ("Tevogen"), each restricted stock unit ("RSU") with respect to shares of Tevogen common stock (each a "Tevogen RSU") that was then unvested was automatically canceled and converted into an award under the Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan with respect to a number of RSUs to be settled in the common stock of the Issuer equal to the product, rounded up to the nearest whole number, of (i) the number of shares of Tevogen common stock subject to the Tevogen RSU as of immediately prior to the Effective Time, multiplied by (ii) approximately 4.8481. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.